Viatris Bundle
How has Viatris shifted its sales and marketing to drive growth?
Viatris pivoted from volume generics to a focused, mix‑improving model emphasizing complex generics, biosimilars, and select brands, backed by precision HCP engagement and an omnichannel commercial approach.
In 2023–2024 Viatris accelerated portfolio reshaping, divesting noncore assets, reducing debt, and redeploying into higher‑value launches to protect margins and drive double‑digit growth in Injectables, Complex Gx, and Eye Care.
Key tactics: targeted field teams, digital omnichannel HCP engagement, tender and institutional reach retained, and selective branded push in ophthalmology and biosimilars; see Viatris Porter's Five Forces Analysis.
How Does Viatris Reach Its Customers?
Viatris employs a multi‑pronged sales channel mix combining hospital tenders, wholesalers, specialty distributors, retail pharmacy networks, direct sales and government procurement to optimize access and margin across generics, biosimilars and branded products.
Channel composition
Hospital/institutional tenders and national wholesalers (e.g., McKesson, AmerisourceBergen/Cencora, Cardinal in the U.S.) anchor generics distribution; specialty distributors and buy‑and‑bill routes support biosimilars and complex therapies.
Retail and pharmacy reach
Retail pharmacy chains and independent pharmacies are served via national wholesalers and B2B e‑commerce portals in select markets to sustain >90% generic substitution alignment with U.S. formularies.
Specialty expansion
Since 2021 Viatris expanded specialty capabilities for biosimilars (trastuzumab, bevacizumab, insulin glargine alliances) and ophthalmology, routing launches through specialty/hospital channels to protect pricing and share.
Emerging markets & government
Government procurement and tenders drive volume in emerging markets, with targeted direct sales and key account teams for branded and specialty product access.
Channel evolution reflects portfolio and commercial shifts focused on margin improvement and access.
Key channel outcomes and capabilities
Omnichannel integration and strategic channel choices have supported stability in core franchises and improved net price realization versus pure retail generics.
- Portfolio reshaping 2022–2024 cut low‑margin retail SKUs and improved gross margin mix, contributing to margin expansion toward target adjusted EBITDA in the high‑20s by 2024–2025.
- Accelerated biosimilar penetration via partnerships (e.g., Biocon Biologics transaction closed 2022) reoriented insulin biosimilar economics while preserving commercial collaborations in multiple markets.
- Deeper hospital/tender penetration in Europe/EMEA where Viatris holds leading or top‑three generic market shares in several countries, enhancing tender win rates.
- Omnichannel CRM linked to field force and distributor data since 2023 prioritized targets by geography and payer access, aiding mid‑single‑digit growth in core franchises despite revenue normalization from divestitures.
For further context on revenue mix and commercial model alignment see Revenue Streams & Business Model of Viatris.
Viatris SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Marketing Tactics Does Viatris Use?
Viatris' marketing tactics prioritize targeted engagement with healthcare professionals, payers, and institutions through compliant omnichannel programs, data-driven personalization, and traditional medical communications to support product access and uptake.
HCP Digital Channels
HCP portals host clinical resources, product monographs and prescribing tools to support decision making and formulary inclusion.
SEO and Paid Search
SEO targets molecule names and therapeutic queries; programmatic and search ads are used where HCP targeting is permitted.
Email Personalization
Segmented email journeys by specialty, prescribing history and formulary status improved open/click rates by double digits after 2023 automation scale-up.
Social and DTC
LinkedIn and YouTube emphasize corporate thought leadership, ESG and disease awareness; selective DTC used for OTC or permitted brands in specific geographies.
Traditional Medical Media
Medical congress symposia, peer‑review journals, CME partnerships and pharmacy trade publications remain core to credibility and clinician reach.
Field Force Enablement
Field reps use next‑best‑action engines within CRM to time visits, trigger samples where legal, and push access updates to increase HCP engagement efficiency.
Data and Tech Stack
Marketing leverages integrated data lakes combining IQVIA/claims, tender results and distributor inventory with CRM activity; MDM maps SKUs across markets for consistent messaging.
- Enterprise CRM: Salesforce for call planning and omnichannel orchestration
- Analytics/BI: Power BI and Tableau for campaign and HEOR insights
- Consent management and MDM to ensure compliant targeting
- Since 2023, marketing automation personalization lifted engagement metrics by double digits
AI and Personalization Pilots
Pilots in 2024 used AI copy optimization for HCP emails and propensity scoring for biosimilar adoption, improving conversion in targeted oncology and ophthalmology accounts.
- Propensity models prioritized accounts for biosimilar uptake, increasing targeted conversions
- AI-optimized messaging improved open/click performance in specialty segments
- Omnichannel virtual detailing supplemented in-person detailing post‑pandemic
- Next‑best‑action nudges improved call plan adherence and rep productivity
Market Access Communications
Value dossiers, HEOR summaries and budget impact models are central to payer negotiations and tender bids, supporting pricing and formulary discussions.
- HEOR outputs feed payer-facing materials for tender success
- Budget impact models used in emerging markets to support uptake cases
- Distributor and pharmacy partnership materials align commercial and access strategies
- Segmentation by payer criteria shapes promotional and contracting tactics
Performance and Metrics
Measurement focuses on HCP engagement rates, prescription uplift, tender win rates and ROI per channel; pilots reported improved conversion especially for biosimilars and specialty therapies.
- CRM-driven KPIs track call plan adherence and next‑best‑action outcomes
- Channel-level ROI evaluated via linked prescribing and claims data
- Formulary inclusion and tender share monitor access success
- Digital engagement metrics tied to downstream prescription behavior
See broader company context in the article Mission, Vision & Core Values of Viatris
Viatris PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
How Is Viatris Positioned in the Market?
Brand Positioning for Viatris centers on accessible, high‑quality, reliable medicines at global scale, promising to 'Empower People Worldwide to Live Healthier at Every Stage of Life.' The company differentiates via breadth across branded, generics and biosimilars, manufacturing scale, and payer‑focused affordability.
Brand promise
Access, quality and reliability at scale: a value proposition pitched to health systems, pharmacies and payers emphasizing predictable supply and cost reduction.
Differentiators
Breadth of portfolio (>10,000 SKUs), manufacturing footprint (40+ facilities) and regulatory performance underpin claims of consistent quality and global reach.
Targeted brand elevation
Selective brand investment in eye care, women’s health and complex generics aligns commercial resources to higher‑value segments and margin retention.
Visual and tonal identity
Clean clinical palette, inclusive imagery, and an evidence‑based pragmatic tone support trust with HCPs and payers.
Positioning pillars
Dependable supply, high‑value biosimilars to lower system spend, and responsible sustainability form the triad of strategic positioning.
Supply reliability
Emphasis on predictable fill rates and tender performance addresses shortages seen in 2023–2024; manufacturing scale (40+ sites) supports continuity.
Biosimilars strategy
Positioned as a high‑value cost reducer for payers; commercial messaging highlights reduced system costs and payer‑friendly economics.
Sustainability & metrics
Recognized on sustainability and DEI indices; 2024 ESG updates reported progress on emissions reduction and expanded patient reach via annual access metrics.
Governance & consistency
Global brand governance enforces alignment across HCP portals, packaging and medical information to preserve a uniform customer experience.
Payer & policy narrative
Leverages industry context—U.S. generics estimated to have saved $408B in 2023—to argue Viatris's role in lowering drug spend and inform payer dialogues.
Commercial responses & focus areas
Competitive approach balances defense against innovator protection and aggressive generics entrants through quality differentiation, complex formulations, and enhanced service levels.
- Focus on complex generics and specialty segments to preserve margin
- Operational KPIs: fill rates, tender performance and pharmacovigilance
- Commercial stories tied to affordability and access to influence policymakers and payers
- Integration of M&A and channel partnerships to expand reach in emerging markets
For deeper context on competitive positioning and market dynamics see Competitors Landscape of Viatris.
Viatris Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Are Viatris’s Most Notable Campaigns?
Key campaigns focused on accelerating biosimilars uptake, expanding eye care presence, reinforcing access and affordability advocacy, and stabilizing reputation post‑merger through targeted, data‑driven communications aligned with Viatris commercial strategy and go‑to‑market priorities.
Biosimilars adoption acceleration (2023–2024)
Objective: drive formulary wins and HCP confidence in oncology and insulin biosimilars after business realignment. Creative: evidence‑first messaging with comparability data, patient access support, and budget impact tools. Channels: payer dossiers, hospital P&T engagements, ASCO/ESMO booths, CRM HCP emails. Results: double‑digit account uptake in targeted EU and emerging markets; improved tender win rates; insulin biosimilar share stabilized despite price pressure. Success factor: HEOR integrated with field pull‑through and inventory reliability.
Eye care growth push (2024)
Objective: build a differentiated ophthalmology and OTC eye‑health presence. Creative: 'clarity and comfort' value story for pharmacists and eye‑care professionals, supported by patient education microsites. Channels: pharmacy trade media, LinkedIn thought leadership, virtual detailing to optometrists. Results: category share gains in select EU markets and improved shelf placement with major retail chains. Lesson: omnichannel pharmacist education plus supply reliability outperforms consumer‑only spend in regulated categories.
Access and affordability advocacy (2022–2025)
Objective: strengthen corporate reputation and policy influence. Creative: data‑rich narratives on system savings, manufacturing quality, and global reach. Channels: corporate reports, policy forums, LinkedIn, media placements. Results: higher corporate engagement metrics, inclusion in sustainability and access rankings, supporting tender credibility. Success factor: credible third‑party statistics and transparent reporting.
Post‑merger reputation & portfolio reshaping (2023)
Objective: signal pivot to higher‑value mix and debt reduction to investors and customers. Creative: clear roadmaps, divestiture updates, pipeline highlights. Channels: earnings webcasts, investor days, trade communications to distributors and payers. Results: clearer SKU rationalization and service continuity, aiding stable relationships during change. Lesson: proactive, data‑driven communication mitigates channel disruption.
Measurement and HEOR integration
Routine use of HEOR and budget‑impact models increased formulary wins; field teams used these tools to secure tenders and payer contracts in 2023–2024.
Omnichannel execution
CRM, virtual detailing and congress engagements produced higher HCP touch rates; pharmacy‑focused campaigns delivered measurable shelf and share improvements in EU markets.
Policy and reputation lift
Corporate reporting and policy forum activity contributed to inclusion in access and sustainability rankings, improving stakeholder trust and tender credibility.
Commercial priorities
Campaigns prioritized formulary access, supply reliability and HEOR evidence to support Viatris sales strategy and Viatris marketing strategy across geographies.
Investor communications
Transparent investor days and earnings webcasts clarified SKU rationalization and expected margin impact, aligning commercial expectations during portfolio reshaping.
Channel strategy lessons
Combining payer dossiers, hospital P&T engagement, and pharmacy partnerships proved more effective for regulated categories than consumer‑only promotion.
Key outcomes and metrics
Campaign performance highlighted measurable commercial improvements linked to the Viatris go‑to‑market plan and sales force effectiveness.
- Double‑digit account uptake for targeted biosimilars in EU/emerging markets
- Improved tender win rates and stabilized insulin biosimilar share under price pressure
- Category share gains and better retail placement for eye‑care in select EU markets
- Higher corporate engagement metrics and inclusion in access/sustainability rankings
Further context on historical strategy and corporate evolution can be found in the Brief History of Viatris.
Viatris Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Viatris Company?
- What is Competitive Landscape of Viatris Company?
- What is Growth Strategy and Future Prospects of Viatris Company?
- How Does Viatris Company Work?
- What are Mission Vision & Core Values of Viatris Company?
- Who Owns Viatris Company?
- What is Customer Demographics and Target Market of Viatris Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.